Indivior Pharmaceuticals, Inc.

Indivior Pharmaceuticals reported strong second-quarter results with net income soaring to $122 million, a 578% increase year-over-year, on net revenue of $343 million. For the six months, net income reached $211 million, up 225%. The company also issued $500 million in Convertible Senior Notes, used to repay $333 million of prior debt, and executed $300 million in share repurchases under its $400 million program.

Indivior Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc. announced a definitive merger agreement to create a diversified CNS biopharmaceutical leader. The transaction is structured as a 100% tax-free stock-for-stock merger, with Supernus shareholders receiving 1.5401 Indivior shares per Supernus share. Prior to closing, Indivior will declare a $1 billion dividend to its pre-closing shareholders. The combined entity is expected to have pro forma net revenues of $2.2 billion and realize at least $125 million in annual cost synergies, with a targeted closing in Q4 2026.

Indivior Pharmaceuticals reported strong second-quarter 2026 financial results, with Total Net Revenue increasing 14% year-over-year to $343 million and GAAP Net Income reaching $122 million. The company also significantly raised its full-year 2026 financial guidance for both Total Net Revenue and Adjusted EBITDA, driven by exceptional SUBLOCADE performance. Additionally, Indivior repurchased $175 million in shares during the quarter and reiterated its proposed merger with Supernus Pharmaceuticals is expected to close in Q4 2026.

Indivior Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc. announced an all-stock merger, creating a diversified CNS biopharmaceutical leader named Supernus, Inc. The combined entity is expected to have $2.2 billion in annual revenues and achieve $125 million in annual cost synergies. Indivior stockholders will own approximately 56.5% of the combined company, and Supernus stockholders will own 43.5%. Indivior will also declare a $1 billion special cash dividend, financed in part by a $650 million term loan.

Indivior Pharmaceuticals reported strong financial results for Q2 2026, with total net revenue increasing 14% year-over-year to $343 million and record Adjusted EBITDA of $186 million, up 111%. The company also raised its full-year 2026 financial guidance, driven by exceptional SUBLOCADE performance, which achieved record quarterly net revenue of $253 million. Indivior repurchased $175 million in shares during the quarter and anticipates closing its proposed merger with Supernus in the fourth quarter.

Indivior Pharmaceuticals, Inc. announced it will release its second quarter 2026 financial results on Tuesday, August 4, 2026, at 7:00 a.m. U.S. EDT. Following the release, CEO Joe Ciaffoni and other leaders will host a live webcast presentation at 8:00 a.m. U.S. EDT. Investors can access the webcast and materials through the company's website, with a replay also available.

Indivior Pharmaceuticals announced findings from two new real-world evidence studies on SUBLOCADE® (extended-release buprenorphine) for opioid use disorder (OUD). The studies showed that adherence to monthly injectable buprenorphine is associated with a significantly lower relapse risk, fewer infection-related complications, and reduced healthcare utilization. Patients on SUBLOCADE were 3.5 to 8.1 times less likely to return to opioid use and experienced a 62% lower incidence of bacteremia and fewer inpatient, emergency, and outpatient visits compared to other MOUD treatments. These findings highlight the benefits of sustained treatment and the potential to reduce costly acute care crises.

Indivior Pharmaceuticals, Inc. announced the elimination of the Chief Scientific Officer position, effective June 1, 2026, leading to the termination of Dr. Christian Heidbreder's employment on December 31, 2026. Additionally, the company held its annual meeting of stockholders on May 13, 2026. Shareholders elected all eight director nominees, approved executive compensation on an advisory basis, and indicated a preference for annual Say-on-Pay votes. PricewaterhouseCoopers LLP US was also ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.

Indivior Pharmaceuticals, Inc. announced it has entered into a $175 million accelerated share repurchase (ASR) agreement with Barclays Bank PLC. This ASR is a component of the company's existing $400 million share repurchase program. Indivior made an upfront payment of $175 million and received an initial delivery of 3,717,473 shares, with final settlement anticipated by late June 2026. The company affirmed that the ASR is not expected to affect its previously issued financial guidance.

Indivior Pharmaceuticals, Inc. reported a significant increase in net revenue to $317 million and net income to $89 million for Q1 2026. The company completed its U.S. domestication in January 2026 and issued $500 million in Convertible Senior Notes due 2031, using proceeds to repay $333 million of prior debt, incurring an $18 million loss on extinguishment. The company also faces ongoing dental litigation with approximately 1,900 cases consolidated.